REMAP-CAP
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia

PREPARE – Platform foR European Preparedness Against (Re-)emerging Epidemics

prepare_icu@umcutrecht.nl

July 2018

NEWSLETTER

REMAP-CAP: an international study on the treatment of severe CAP in patients admitted to the Intensive Care Unit

Creation of the Pandemic Domain

During the last Prepare annual meeting, it was decided to start with the construction of a Pandemic Domain. This domain can be added to the current three active domains. This domain becomes activated when there is a severe threat of a worldwide disease that results in the admittance of patients with CAP to the ICU. For now, an international working group is being formed and the first task is to change parts of the core protocol to make it suitable for implementing a Pandemic domain. Thereafter, specific interventions will be designed which will result in Domain Specific Appendices.

Are you interested to join?

If you would like to join the REMAP-CAP Study, please send an email to the general REMAP-CAP email address (below). The members of the Regional Coordinating Committee will provide you with essential information and guide you through the process of becoming a member of the REMAP-CAP family.

First patient included in Ireland

The first subject was included very soon after official approval to start the study in St Vincent's Hospital in Dublin. This was slightly unexpected by the study team because the influenza season had already come to a halt. The patient was successfully randomized in the new electronic Case Record Form. This was the first subject in the EU outside the Netherlands and gave the EU regional coordinating team the opportunity to test all procedures which have been created during the past years. The experiences have been discussed with the local team and will be used in a Frequently Asked Questions (FAQ) document.

Full ethics approval in the United Kingdom

Recently, the REMAP-CAP study was fully approved by national ethical committees and competent authorities in the United Kingdom. Because of the uncommon way the protocol is designed, the study team receives in general much attention and comments from regulatory authorities. This results in delays in the initiation of sites. Fortunately this process is finished for the United Kingdom and we are moving forward with local contract negotiations.

Successful start of German Network

On Friday 29th of June, 16 intensivist and study coordinators attended the first REMAP-CAP investigator meeting in Germany. This was considered the kickoff of the German Network led by Frank Brunkhorst as PI and Isabella Schiller as Project Manager. At the meeting, the participants were informed about the protocol and study logisitics. Afterwards there was a good discussion about interpretation and clincal impact of the different domains in the clinic. The next step for the German Network will be submission to the different ethical committees in Germany.